Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18945317 | GLABRIDIN COMPOSITION WITH HIGH SKIN PERMEABILITY, AND PREPARATION METHOD AND USE THEREOF | November 2024 | February 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18892208 | KRAS MODULATORS AND USES THEREOF | September 2024 | March 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18761732 | METHOD FOR PRODUCING GLYCERIDES OF HYDROXYCARBOXYLIC ACIDS | July 2024 | July 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18762588 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | July 2024 | October 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18761559 | DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF | July 2024 | March 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18665823 | N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods | May 2024 | October 2025 | Allow | 17 | 1 | 0 | No | No |
| 18611026 | METHOD FOR PRODUCING 1,3-DIOLEIN FROM BIOMASS | March 2024 | August 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18432829 | TOPICAL TREATMENT OF WOUNDS WITH STATINS AND CHOLESTEROL FOR SCAR REDUCTION | February 2024 | August 2025 | Allow | 18 | 1 | 0 | No | No |
| 18291206 | CRYSTAL FORM OF COMPOUND REPRESENTED BY FORMULA I, AND PREPARATION THEREFOR AND APPLICATION THEREOF | January 2024 | March 2026 | Allow | 26 | 0 | 0 | Yes | No |
| 18580809 | Reduced Odor Formaldehyde-Containing Antiseptic Lotion | January 2024 | June 2025 | Allow | 17 | 0 | 0 | Yes | No |
| 18571556 | NOVEL INHIBITORS OF 17ß-HSD7 AND USES THEREOF | December 2023 | February 2026 | Allow | 26 | 0 | 0 | Yes | No |
| 18506944 | TREATMENT OF CARDIOPULMONARY DISORDERS | November 2023 | April 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18385535 | 8-(4-BROMOBENZYLIDENEAMINO)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUND | October 2023 | April 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18385802 | 4,4'-NAPHTHALENE-1,5-DIYLBIS(DIAZENE-2,1-DIYL)DIPHENOL AS AN ANTIOXIDANT COMPOUND | October 2023 | April 2024 | Allow | 6 | 1 | 0 | No | No |
| 18497653 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | October 2023 | April 2025 | Allow | 18 | 1 | 0 | No | No |
| 18553969 | HIGH POTENCY EMULSIONS | October 2023 | March 2026 | Abandon | 29 | 2 | 0 | No | No |
| 18474538 | METHODS OF TREATING DEPRESSION WITH VORTIOXETINE | September 2023 | August 2025 | Allow | 23 | 1 | 0 | Yes | No |
| 18371095 | SELECTIVE COX-2 INHIBITION OF 2-(SUBSTITUTED BENZYL)-3,5,6,7-TETRAHYDRO-4H-CYCLOPENTA[4,5]THIENO[2,3-d]PYRIMIDIN-4-ONES AND 4-FLUORO-N-(4-OXO-3,5,6,7-TETRAHYDRO-4H-CYCLOPENTA[4,5]THIENO[2,3-d]PYRIMIDIN-2-YL)BENZAMIDE AS ANTI-INFLAMMATORY AGENTS | September 2023 | October 2024 | Allow | 13 | 4 | 0 | Yes | No |
| 18348193 | FORMULATIONS AND METHODS RELATED TO EYE IRRITATION AND RELATED | July 2023 | September 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18348237 | RELATED FORMULATIONS AND METHODS RELATED TO EYE IRRITATION | July 2023 | December 2025 | Allow | 29 | 1 | 0 | Yes | No |
| 18257002 | SEALING FLUID FOR SEALING CAPSULES | June 2023 | November 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 18320284 | DETERGENT FORMULATIONS | May 2023 | October 2025 | Allow | 29 | 0 | 0 | Yes | No |
| 18192210 | Methods And Compositions For The Treatment Of Cancer | March 2023 | October 2024 | Allow | 19 | 1 | 0 | No | No |
| 18026250 | NEAR-INFRARED NANO-PHOTOSENSITIZER, AND PREPARATION METHOD AND USE THEREOF | March 2023 | October 2023 | Allow | 7 | 0 | 0 | Yes | No |
| 18176962 | TREATING EXTRAPYRAMIDAL SYNDROME USING TRAPIDIL | March 2023 | December 2024 | Allow | 21 | 1 | 0 | No | No |
| 18107162 | METHOD FOR INDUCING TUMOR REGRESSION | February 2023 | February 2025 | Allow | 24 | 1 | 0 | No | No |
| 18101986 | FATTY LIVER DISEASE TREATMENT USING GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | January 2023 | December 2024 | Allow | 23 | 1 | 0 | No | No |
| 18150656 | Methods of Treating Amyotrophic Lateral Sclerosis and Symptoms | January 2023 | July 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17976471 | Treatment of Cancer with TOR Kinase Inhibitors | October 2022 | June 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17945311 | OINTMENTS FOR TREATING DRY SKIN | September 2022 | April 2025 | Allow | 31 | 1 | 0 | No | No |
| 17882949 | COMBINATION THERAPY USING ENANTIOPURE, OXY-SUBSTITUTED, DEUTERIUM-ENRICHED 5-(BENZYL)-5-DEUTERO-THIAZOLIDINE-2,4-DIONES FOR TREATMENT OF MEDICAL DISORDERS | August 2022 | February 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17874621 | COMPOUNDS FOR TREATING BRAIN CANCER | July 2022 | March 2025 | Allow | 31 | 2 | 0 | No | No |
| 17867792 | DIAGNOSTICS | July 2022 | July 2025 | Allow | 36 | 1 | 0 | No | No |
| 17867370 | AQUEOUS FORMULATION COMPRISING PARACETAMOL AND IBUPROFEN | July 2022 | May 2024 | Allow | 22 | 1 | 0 | No | No |
| 17831710 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | June 2022 | August 2025 | Allow | 38 | 1 | 0 | No | No |
| 17826602 | Aqueous Nebulization Composition | May 2022 | February 2025 | Allow | 32 | 2 | 0 | No | No |
| 17780284 | COMPOSITION CONTAINING AROMATIC HETEROCYCLIC COMPOUND IN AMORPHOUS FORM, AND PREPARATION METHOD THEREFOR AND USE THEREOF | May 2022 | March 2026 | Abandon | 46 | 0 | 1 | No | No |
| 17752648 | Hybrid Mycelial Cellulose Sheet and Preparation Thereof | May 2022 | February 2023 | Allow | 9 | 2 | 1 | Yes | No |
| 17752676 | METHOD FOR INDUCING TUMOR REGRESSION | May 2022 | November 2024 | Allow | 30 | 1 | 0 | No | No |
| 17750969 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | May 2022 | April 2025 | Abandon | 35 | 2 | 0 | No | No |
| 17749312 | METHODS FOR POTENTIATING A BIOCIDE | May 2022 | September 2025 | Abandon | 40 | 2 | 0 | No | No |
| 17776802 | SALTS OF TRANEXAMIC ACID ESTERS | May 2022 | November 2025 | Allow | 42 | 1 | 0 | No | No |
| 17744224 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | May 2022 | March 2024 | Allow | 23 | 1 | 0 | No | No |
| 17662866 | METHOD FOR TREATING INFLAMMATORY DISORDERS | May 2022 | May 2024 | Allow | 24 | 2 | 0 | No | No |
| 17729205 | LSD SALT CRYSTAL FORMS | April 2022 | September 2025 | Allow | 41 | 2 | 1 | No | No |
| 17724589 | Compounds And Compositions As Protein Kinase Inhibitors | April 2022 | August 2023 | Allow | 16 | 0 | 0 | No | No |
| 17723163 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | April 2022 | March 2025 | Allow | 35 | 2 | 1 | Yes | No |
| 17691399 | PREECLAMPSIA BIOMARKERS AND RELATED SYSTEMS AND METHODS | March 2022 | November 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17689271 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF | March 2022 | October 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17631677 | PRODUCING METHOD OF COSMETICS AND COSMETICS | January 2022 | January 2026 | Abandon | 47 | 1 | 0 | No | No |
| 17588033 | PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND VE | January 2022 | May 2024 | Allow | 28 | 1 | 0 | Yes | No |
| 17630709 | SORAFENIB PHARMACEUTICAL COMPOSITION WITH HIGH BIOAVAILABILITY AND USE THEREOF | January 2022 | October 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17627967 | PYRAZOLO[3,4-D]PYRROLO[1,2-B]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | January 2022 | February 2025 | Allow | 37 | 0 | 0 | Yes | No |
| 17572493 | COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENT | January 2022 | February 2025 | Allow | 37 | 2 | 0 | No | No |
| 17566804 | Methods and Compositions for the Treatment of Multiple Sclerosis | December 2021 | July 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17538749 | METHODS OF USING DIPIVEFRIN | November 2021 | September 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17534817 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | November 2021 | December 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17529078 | Pharmaceutical Composition | November 2021 | July 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17528959 | COMPOSITIONS, USES AND METHODS FOR TREATMENT OF INFERTILITY AND SUBFERTILITY | November 2021 | July 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17528510 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | November 2021 | April 2023 | Allow | 16 | 0 | 0 | Yes | No |
| 17517765 | HIGH-CONTENT ABAMECTIN EMULSIFIABLE CONCENTRATE | November 2021 | August 2025 | Allow | 46 | 4 | 0 | No | No |
| 17515800 | PEPTIDE FOR TREATING SEPSIS DERIVED FROM Rv2626c PROTEIN OF MYCOBACTERIUM TUBERCULOSIS | November 2021 | September 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17510572 | MIXTURES OF SABADILLA ALKALOIDS AND DIAMIDES AND USES THEREOF | October 2021 | June 2024 | Abandon | 31 | 0 | 1 | No | No |
| 17502899 | AQUEOUS FORMULATION COMPRISING PARACETAMOL AND IBUPROFEN | October 2021 | February 2022 | Allow | 4 | 1 | 0 | Yes | No |
| 17484921 | Combination Therapy for Male Sexual Dysfunction | September 2021 | May 2025 | Abandon | 44 | 2 | 0 | Yes | No |
| 17479649 | DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST | September 2021 | October 2024 | Abandon | 36 | 2 | 0 | No | No |
| 17460693 | NON-INFECTIVE NASAL SYMPTOM MANAGEMENT COMPOSITIONS AND METHODS | August 2021 | February 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17433898 | COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY INSUFFICIENCY | August 2021 | March 2026 | Abandon | 55 | 3 | 0 | No | No |
| 17404579 | Pyrazoline Dihydroquinolones, Pharmaceutical Compositions, and Uses | August 2021 | January 2025 | Allow | 41 | 1 | 1 | No | No |
| 17398622 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | August 2021 | July 2024 | Allow | 35 | 2 | 0 | No | No |
| 17379083 | METHOD FOR PRODUCING GLYCERIDES OF HYDROXYCARBOXYLIC ACIDS | July 2021 | February 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17374488 | TOPICAL TREATMENT OF WOUNDS WITH STATINS AND CHOLESTEROL FOR SCAR REDUCTION | July 2021 | September 2023 | Allow | 26 | 1 | 1 | Yes | No |
| 17365886 | Method of Treatment for Ketamine Infusion | July 2021 | February 2023 | Abandon | 20 | 2 | 0 | Yes | No |
| 17418113 | Therapeutic agent for RNA viral infection comprising a combination of pyrazine derivative and compound which increases amount of pyrazine derivative ribose triphosphate in cell | June 2021 | July 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17415966 | Intranasal Formulation | June 2021 | March 2025 | Allow | 45 | 2 | 0 | No | No |
| 17296568 | AN ANTIMICROBIAL COMPOSITION | May 2021 | November 2024 | Allow | 42 | 1 | 0 | No | No |
| 17314647 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | May 2021 | March 2022 | Abandon | 10 | 2 | 0 | Yes | No |
| 17309216 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | May 2021 | February 2024 | Allow | 34 | 0 | 0 | No | No |
| 17246143 | GLYCOSIDASE INHIBITORS | April 2021 | May 2024 | Allow | 36 | 1 | 1 | No | No |
| 17290224 | SOLID DISPERSIONS FOR TREATMENT OF CANCER | April 2021 | May 2025 | Abandon | 49 | 3 | 0 | No | No |
| 17234574 | PREECLAMPSIA BIOMARKERS AND RELATED SYSTEMS AND METHODS | April 2021 | February 2022 | Allow | 9 | 1 | 0 | Yes | No |
| 17229561 | METHOD OF TREATMENT | April 2021 | February 2024 | Abandon | 34 | 2 | 0 | No | No |
| 17225472 | Body Sculpting | April 2021 | August 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17222953 | Method and Composition for Enhancing the Quality and Benefits of Sleep | April 2021 | May 2025 | Allow | 49 | 3 | 0 | Yes | No |
| 17220515 | METHODS OF TREATING DEPRESSION WITH VORTIOXETINE | April 2021 | September 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17218814 | COMPOSITION CONTAINING ECTOINE OR HYDROXYECTOINE AS AN ACTIVE SUBSTANCE FOR PROMOTING THE REGENERATION OF INJURED BODY TISSUE | March 2021 | January 2025 | Abandon | 45 | 3 | 0 | No | No |
| 17219733 | BOWEL CLEANSING COMPOSITION | March 2021 | September 2023 | Abandon | 29 | 4 | 0 | Yes | No |
| 17215466 | ENVENOMATION THERAPIES AND RELATED PHARMACEUTICAL COMPOSITIONS, SYSTEMS AND KITS | March 2021 | December 2024 | Allow | 44 | 2 | 1 | Yes | Yes |
| 17209078 | COMPOSITIONS OF A POLYORTHOESTER AND AN ORGANIC ACID EXCIPIENT | March 2021 | September 2023 | Allow | 30 | 1 | 0 | Yes | No |
| 17206362 | Salts of Zuclomiphene | March 2021 | October 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17203467 | FORMULATIONS AND METHODS RELATED TO EYE IRRITATION | March 2021 | July 2024 | Allow | 40 | 3 | 1 | No | No |
| 17168876 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | February 2021 | July 2023 | Allow | 30 | 2 | 0 | No | No |
| 17169008 | SALTS AND SOLID FORMS AND PROCESSES OF PREPARING A PI3K INHIBITOR | February 2021 | February 2026 | Abandon | 60 | 2 | 2 | No | No |
| 17166927 | SOLID FORMS OF APOL1 INHIBITOR AND METHODS OF USING SAME | February 2021 | February 2024 | Abandon | 36 | 2 | 0 | Yes | No |
| 17145430 | MEDICAL USE OF COMPOUND III | January 2021 | March 2026 | Abandon | 60 | 6 | 0 | Yes | Yes |
| 17258610 | B-CELL IMMUNOTHERAPY IN CANCER TREATMENT | January 2021 | April 2025 | Allow | 51 | 2 | 0 | Yes | No |
| 17123380 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | December 2020 | August 2024 | Abandon | 44 | 2 | 1 | No | No |
| 17121567 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIEMETIC COMPOUNDS AND POLYORTHOESTER | December 2020 | June 2023 | Abandon | 30 | 0 | 1 | No | No |
| 17117559 | ANTICOAGULANT REVERSAL AGENTS | December 2020 | December 2023 | Abandon | 37 | 1 | 1 | No | No |
| 17111288 | FATTY LIVER DISEASE TREATMENT USING GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | December 2020 | January 2023 | Allow | 25 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BORI, IBRAHIM D.
With a 31.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 12.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BORI, IBRAHIM D works in Art Unit 1629 and has examined 666 patent applications in our dataset. With an allowance rate of 43.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner BORI, IBRAHIM D's allowance rate of 43.4% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BORI, IBRAHIM D receive 2.25 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BORI, IBRAHIM D is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +47.5% benefit to allowance rate for applications examined by BORI, IBRAHIM D. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 14.8% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 20.8% of cases where such amendments are filed. This entry rate is in the 26% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 72.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 59% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 61.0% of appeals filed. This is in the 38% percentile among all examiners. Of these withdrawals, 60.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 75.4% are granted (fully or in part). This grant rate is in the 81% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 59% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.8% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.